Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha

An important emerging form of immunotherapy targeting B cell malignancies is chimeric antigen receptor (CAR) T cell therapy. Despite encouraging response rates of anti-CD19 CAR T cell therapy in B cell lymphomas, limited durability of response necessitates further study to potentiate CAR T cell effi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Interferon Cytokine Res
Egile Nagusiak: Young, Patricia A., Yamada, Reiko E., Trinh, Kham R., Vasuthasawat, Alex, De Oliveira, Satiro, Yamada, Douglas H., Morrison, Sherie L., Timmerman, John M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Mary Ann Liebert, Inc. 2018
Gaiak:
Research Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007814/
https://ncbi.nlm.nih.gov/pubmed/29920129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jir.2018.0030
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak